Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Duloxetine Versus Placebo in the Treatment of FMS
- Conditions
- First Posted Date
- 2005-10-05
- Last Posted Date
- 2007-08-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 320
- Registration Number
- NCT00233025
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom
Complaints Associated With Use of Pre-Filled Pen B With Type 2 Diabetics on Twice-Daily Insulin
- Conditions
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2007-06-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 370
- Registration Number
- NCT00231725
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Middlesbrough, United Kingdom
Neuropsychological Functioning in Children With Attention-Deficit/Hyperactivity Disorder.
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 40
- Registration Number
- NCT00216918
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Quebec, Canada
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 120
- Registration Number
- NCT00207116
- Locations
- 🇺🇸
Local Institution, Newark, Delaware, United States
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 110
- Registration Number
- NCT00207155
- Locations
- 🇪🇸
Local Institution, Barcelona, Spain
Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 33
- Registration Number
- NCT00207077
- Locations
- 🇺🇸
Christiana Care Health Services, Inc., Newark, Delaware, United States
Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 Diabetes
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-10-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 60
- Registration Number
- NCT00191178
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician, Charlottesville, Virginia, United States
Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-01-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1116
- Registration Number
- NCT00191282
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-651-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician, Liverpool, United Kingdom
Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-07-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 65
- Registration Number
- NCT00191789
- Locations
- 🇮🇳
For additional information regarding investigative sites for this clinical trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT -5 hours, EST), or speak with your personal physician., Delhi, India
Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-10-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 320
- Registration Number
- NCT00191464
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponce, Puerto Rico